Close X


Call: Personalised Medicine

Logo
Programme
Horizon 2020
Acronym H2020
Type of Fund Action programme
Description of programme
"Horizon 2020"
Horizon 2020 is the biggest EU Research and Innovation programme with nearly 80 billion € of funding available over 7 years (2014 to 2020). Apart from classic research projects, Horizon 2020 also funds innovation projects and pilot-projects in different fields.
The programme is divided into three different sections:
  1. Excellent Science
  2. Industrial Leadership
  3. Societal Challenges
Countries eligible for funding are: The EU-Member States, Iceland, Norway, Albania, Bosnia and Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia, Turkey, Moldova, Switzerland, Ukraine, Faroe Islands, Israel, Tunisia, Georgia, Armenia.
Link http://ec.europa.eu/programmes/horizon2020/
Description of programme
"Health, Demographic Change and Wellbeing"

Responding to the challenge of an aging population, research and innovation (R&I) under Horizon 2020 is an investment in better health for all. It aims to keep older people active and independent for longer and supports the development of new, safer and more effective interventions. R&I under Horizon 2020 also contributes to the sustainability of health and care systems.

Call
Personalised Medicine
Description of call
"Personalised Medicine"

The main policy objectives are to improve health and well-being outcomes, to promote healthy and active ageing, to promote market growth, job creation, and the EU as a global leader in the health area. The funded  projects will support the development of evidence based health and care policies, resulting from scientific research data, ICT solutions and good practices in interventions improving efficiency and quality of health and care systems.

Proposals are invited against the following topic(s):

Valorisation of FP7 Health and H2020 SC1 research results

Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine

Implementing the Strategic Research Agenda on Personalised Medicine

Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance

Coordinating personalised medicine research

Towards an ERA-NET for building sustainable and resilient health system models

Global Alliance for Chronic Diseases (GACD)

Actions to bridge the divide in European health research and innovation

Support for Europe’s leading Health ICT SMEs

Coordinated action to support the recognition of Silver Economy opportunities arising from demographic change

Digital health literacy

Healthcare Workforce IT skills

EU-US interoperability roadmap

EU eHealth Interoperability conformity assessment

Standardisation needs in the field of ICT for Active and Healthy Ageing

Multi omics for personalised therapies addressing diseases of the immune system

New concepts in patient stratification

Diagnostic characterisation of rare diseases

Networking and optimising the use of population and patient cohorts at EU level

The European Human Biomonitoring Initiative

Vaccine development for malaria and/or neglected infectious diseases

Promoting mental health and well-being in the young

New therapies for rare diseases

New therapies for chronic diseases

Comparing the effectiveness of existing healthcare interventions in the adult population

Clinical research on regenerative medicine

PCP - eHealth innovation in empowering the patient

PPI for deployment and scaling up of ICT solutions for active and healthy ageing

EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities

Personalised coaching for well-being and care of people as they age

In-silico trials for developing and assessing biomedical products

Personalised computer models and in-silico systems for well-being

Big Data supporting Public Health policies

PPI for uptake of standards for the exchange of digitalised healthcare records

Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector

Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries

 

 

Link https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-sc1-2016-2017.html#c,topics=callIdentifier/t/H2020-SC1-2016-2017/1/1/1&callStatus/t/Forthcoming/1/1/0&callStatus/t/Open/1/1/0&callStatus/t/Closed/1/1/0&+identifier/desc
Thematic Focus Biotechnology, Research, Health, Innovation, Technologies
Funding area EU Member States
Candidate Countries
Iceland / Ísland
Moldova
Norway / Norge
Switzerland / Schweiz / Suisse / Svizzera
Others
Select Origin of Applicant EU Member States


Albania / Shqipëria
Bosnia and Herzegovina
Former Yugoslav Republic of Macedonia / поранешна југословенска Република Македонија
Iceland / Ísland
Moldova
Montenegro / Crna Gora/Црна Гора
Norway / Norge
Serbia / Сpбија
Switzerland / Schweiz / Suisse / Svizzera
Turkey / Türkiye
Ukraine / Україна Oukraïna
Others
Eligible applicants Research Institution, Small and Medium Sized Enterprises, SMEs (between 10 and 249 employees), Start Up Company, University, Enterprise (more than 250 employees or not defined), Association
Project Partner Yes
Project Partner Details

Depending on the activity under this call, the reqiured number of partners is between one and three legal entities each of which is established in a different EU Member State or Horizon2020 associated country.

 

For The European Human Biomonitoring Initiative -

At least five legal entities. Each of the five must be established in a

different EU Member State or Horizon2020 associated country. All

five legal entities must be independent of each other

Recurring Call No
Financial details

The funding rate for actopn PPI for deployment and scaling up of ICT solutions for active and healthy ageing and PPI for uptake of standards for the exchange of digitalised healthcare record is limited to 35% of the total eligible costs to leverage co-financing from the procurers in this specific case.

 

The funding rate for eHealth innovation in empowering the patient is limited to 90% of the total eligible costs to leverage co-financing from the procurers in this specific case.

Contact Details

Link to the National Contact Point Finder.


Register now and benefit from additional services - it is free of cost!

Loading Animation